Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed low-grade, follicular B-cell, or mantle cell non-Hodgkin's lymphoma Bone marrow biopsy required for pretreatment evaluation Unilateral bone marrow biopsy allowed Core biopsies allowed if they contain adequate tissue for primary diagnosis and immunophenotyping Relapsed or refractory disease as defined by disease progression after initial complete response (CR) or failure to achieve CR No bone marrow involvement ≥ 25% within the past 30 days No pleural effusion or significant ascites No active CNS involvement PATIENT CHARACTERISTICS: ECOG performance status 0-2 Life expectancy ≥ 3 months Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 AST ≤ 2.5 times upper limit of normal (ULN) Total bilirubin ≤ 2.5 times ULN Creatinine clearance ≥ 50 mL/min Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Hepatitis B surface antigen negative No current infection with hepatitis B virus No HIV positivity No neuropathy or neuropathic pain ≥ grade 2 No history of allergic reaction to boron or mannitol No active serious infection or medical or psychiatric illness that would preclude study therapy No other malignancy within the past 5 years except for the following: Basal cell or squamous cell carcinoma of the skin that has been completely resected In situ malignancy that has been completely resected T1-T2a, N0, M0 prostate cancer treated with a prostatectomy or radiotherapy within the past 2 years with an undetectable PSA level No other condition, including any of the following: Myocardial infarction within the past 6 months New York Heart Association class III-IV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmias Electrocardiographic evidence of acute ischemia or active conduction system abnormalities PRIOR CONCURRENT THERAPY: Recovered from all prior therapy More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgical resection of malignancy No limitations on the number of prior therapies More than 4 weeks since prior major surgery More than 14 days since prior filgrastim (G-CSF) or sargramostim (GM-CSF) More than 14 days since prior and no other concurrent investigational agents Concurrent participation in a nontreatment study allowed No prior radioimmunotherapy